| The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. Y Qian, BJ Gurley, JS Markowitz Journal of clinical psychopharmacology, 2019 | 131 | 2019 |
| Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era ZP Bulman, L Chen, TJ Walsh, MJ Satlin, Y Qian, JB Bulitta, CA Peloquin, ... MBio 8 (4), 10.1128/mbio. 00540-17, 2017 | 59 | 2017 |
| In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites Y Qian, X Wang, JS Markowitz Drug Metabolism and Disposition 47 (5), 465-472, 2019 | 44 | 2019 |
| Natural products as modulators of CES1 activity Y Qian, JS Markowitz Drug Metabolism and Disposition 48 (10), 993-1007, 2020 | 20 | 2020 |
| The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin Y Qian, TK Gilliland, JS Markowitz Chemico-Biological Interactions 316, 108914, 2020 | 18 | 2020 |
| Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models Y Qian, JS Markowitz Drug Metabolism and Disposition 50 (7), 968-979, 2022 | 12 | 2022 |
| The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects JS Markowitz, L De Faria, Q Zhang, PW Melchert, RF Frye, BO Klee, ... Medical Cannabis and Cannabinoids 5 (1), 199-206, 2022 | 8 | 2022 |
| Inhibition of 2‐methoxyestradiol glucuronidation by probenecid Y Qian, A Sherbini, B Matin, Y Zhao, J Castellot, DJ Greenblatt Journal of Pharmacy and Pharmacology 67 (11), 1585-1592, 2015 | 7 | 2015 |
| Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis MEF Mohamed, Y Qian, R D'Cunha, T Sligh, LK Ferris, A Eldred, GF Levy, ... Clinical and Translational Science 17 (1), e13682, 2024 | 4 | 2024 |
| In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) Kavalactones PW Melchert, Y Qian, Q Zhang, BO Klee, C Xing, JS Markowitz Chemico-Biological Interactions 357, 109883, 2022 | 4 | 2022 |
| OP0164 SAFETY AND EFFICACY OF UPADACITINIB FOR PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, PHASE 1 TRIAL H Brunner, G Horneff, I Foeldvari, J Anton, ME Mohamed, Y Qian, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 108-109, 2023 | 3 | 2023 |
| POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS Y Qian, A Shmagel, S Hao, G Horneff, H Brunner, H Camp, W Liu, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 666-667, 2023 | 2 | 2023 |
| Involvement of esterases in the pulmonary metabolism of beclomethasone dipropionate and the potential influence of cannabis use Y Qian, PW Melchert, JS Markowitz Chemico-Biological Interactions 368, 110228, 2022 | 1 | 2022 |
| Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis Y Qian, EM Raymundo, S Hao, K Unnebrink, GF Levy, HD Teixeira, ... Clinical Therapeutics, 2024 | | 2024 |
| Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial S Tyring, A Moore, A Morita, HC Hong, IH Song, J Eccleston, G Levy, ... Clinical and Experimental Dermatology, llae152, 2024 | | 2024 |
| Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug … J Zhou, Y Qian, Y Lang, Y Zhang, X Tao, B Moya, ARM Sayed, ... Antimicrobial Agents and Chemotherapy 68 (3), e01399-23, 2024 | | 2024 |
| Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults MEF Mohamed, Y Qian, R D'Cunha, S Hao, R Carcereri De Prati, GF Levy, ... Clinical Pharmacology in Drug Development, 2024 | | 2024 |
| Coproporphyrin‐I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug–Drug Interactions: Cedirogant Case Study R Kikuchi, Y Qian, M Badawi, JP Savaryn, S Gannu, A Eldred, S Hao, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| 43227 Pharmacokinetics, Safety, and Tolerability of Cedirogant, a RORyt Inverse Agonist, in Healthy Volunteers ME Mohamed, Y Qian, R D’Cunha, S Hao, RC De Prati, W Liu Journal of the American Academy of Dermatology 89 (3), AB207, 2023 | | 2023 |
| Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients Y Qian, F Cai, T Sornasse, J Shen, H Camp, ME Mohamed ARTHRITIS & RHEUMATOLOGY 74, 584-585, 2022 | | 2022 |
